EUVIMEDEUVIMED entdecken
Open Access

System-Level Transformations to Increase Patient Participation in Clinical Trials

Nicole E Caston iD, Luqin Deng, Courtney P Williams iD, Emily B Levitan iD, Andres Azuero iD, Russell Griffin, Karen L Smith iD, Antonio C Wolff iD, Michelle E Melisko iD, Eileen H Shinn iD, Kathleen Gallagher iD, Rebekah Angove iD und 2 weitere

JCO Oncology Practice · 2025

DOI: 10.1200/op-24-00736 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, 2025. Verfasst von Nicole E Caston und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hematology and Oncology, University of Alabama at Birmingham (UAB), Birmingham, AL. Hauptthemen laut MEDLINE: Patient Participation, COVID-19, Clinical Trials as Topic, Breast Neoplasms. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Over the course of the COVID-19 pandemic, the Food and Drug Administration allowed cancer clinical trials to make modifications. As policymakers consider sustaining these modifications, understanding patient perspectives on impact is critical. METHODS This cross-sectional study used survey data collected between August 2021 and September 2021 by the Translational Breast Cancer Research Consortium and December 2022 by Patient Advocate Foundation among female breast cancer survivors. Respondents reported how changes to location, telemedicine, convenience, and opting out of certain procedures would affect their willingness to participate in a trial. Respondents' county-level vulnerability was determined using five-digit Federal Information Processing Standard codes to link to the Social Vulnerability Index (SVI) overall theme (range, 0-1). According to the SVI, the most vulnerable counties are those in the upper 10% of the overall theme. Model-estimated odds ratios (ORs) and 95% CIs were estimated using multinomial logistic regression models to explore the association between county-level social vulnerability and willingness to participate. RESULTS Overall, 573 women were included, 12% lived in the most vulnerable counties, and 18% had previous trial participation. Over half (53%) reported that they would be very willing to participate in a trial that offered medication delivery to the home. When compared with all other counties, respondents in most vulnerable counties did not have increased willingness to participate in a trial using telemedicine (OR, 0.21 [95% CI, 0.07 to 0.63]). Results were similar for all other trial modifications, though not statistically significant. CONCLUSION Our sample of breast cancer survivors viewed trial modifications favorably. However, respondents in the most vulnerable counties were less likely to be influenced by these modifications. Research is needed to understand if additional modifications would influence participation of this vulnerable population.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Patient ParticipationCOVID-19Clinical Trials as TopicBreast NeoplasmsHumansFemaleCross-Sectional StudiesMiddle AgedAdultAgedCancer SurvivorsSARS-CoV-2Surveys and Questionnaires

Autor:innen und Institutionen

  • Department of Medicine, Division of Hematology and Oncology, University of Alabama at Birmingham (UAB), Birmingham, AL.
  • University of Alabama at Birmingham, Department of Epidemiology, Birmingham, AL.
  • University of Alabama at Birmingham, Division of Preventive Medicine, Birmingham, AL.
  • University of Alabama at Birmingham, School of Nursing, Birmingham, AL.
  • Merck, Rahway, NJ.
  • Johns Hopkins University Sidney Kimmel Cancer Center, Baltimore, MD.

ORCID-Profile: Nicole E Caston, Courtney P Williams, Emily B Levitan, Andres Azuero, Karen L Smith, Antonio C Wolff, Michelle E Melisko, Eileen H Shinn, Kathleen Gallagher, Rebekah Angove, Stephanie B Wheeler, Gabrielle B Rocque

Förderung

  • NCI NIH HHS

Zitieren

APA

Caston, N. E., Deng, L., Williams, C. P., Levitan, E. B., Azuero, A., Griffin, R., Smith, K. L., Wolff, A. C., Melisko, M. E., Shinn, E. H., Gallagher, K., Angove, R., Wheeler, S. B., & Rocque, G. B. (2025). System-Level Transformations to Increase Patient Participation in Clinical Trials. JCO Oncology Practice. https://doi.org/10.1200/op-24-00736

Vancouver

Caston NE, Deng L, Williams CP, Levitan EB, Azuero A, Griffin R, et al. System-Level Transformations to Increase Patient Participation in Clinical Trials. JCO Oncology Practice. 2025. doi:10.1200/op-24-00736

BibTeX
@article{Caston2025,
  author = {Caston, Nicole E and Deng, Luqin and Williams, Courtney P and Levitan, Emily B and Azuero, Andres and Griffin, Russell and Smith, Karen L and Wolff, Antonio C and Melisko, Michelle E and Shinn, Eileen H and Gallagher, Kathleen and Angove, Rebekah and Wheeler, Stephanie B and Rocque, Gabrielle B},
  title = {System-Level Transformations to Increase Patient Participation in Clinical Trials},
  journal = {JCO Oncology Practice},
  year = {2025},
  doi = {10.1200/op-24-00736}
}
Kostenlos starten →